Top Page
Imagion Biosystems Ltd.
(Sydney:IBX)
Imagion Biosystems Ltd. (IBX) vs. S&P 500 (SPY)
Imagion Biosystems Ltd. Business Overview & Revenue Model
Imagion Biosystems Ltd. Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.67M | 1.37M | 473.43K | 232.87K | 205.72K | Gross Profit |
| 2.26M | -3.88M | -3.14M | -2.47M | -2.66M | EBIT |
| -756.55K | -15.81M | -9.81M | -6.02M | -5.36M | EBITDA |
| -700.09K | -10.30M | -9.49M | -5.90M | -5.19M | Net Income Common Stockholders |
| -2.07M | -12.47M | -9.81M | -8.64M | -7.80M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 2.67M | 227.08K | 4.45M | 13.39M | 13.20M | Total Assets |
| 2.80M | 4.59M | 9.98M | 14.12M | 14.12M | Total Debt |
| 2.85M | 6.04M | 4.60M | 46.02K | 660.98K | Net Debt |
| 176.78K | 5.81M | 158.27K | -13.35M | -12.54M | Total Liabilities |
| 5.09M | 8.37M | 5.30M | 809.88K | 1.21M | Stockholders Equity |
| -2.28M | -3.79M | 4.68M | 13.31M | 12.91M |
| Cash Flow | Free Cash Flow | |||
| -1.27M | -8.51M | -9.21M | -5.29M | -4.63M | Operating Cash Flow |
| -1.27M | -8.32M | -8.70M | -5.07M | -4.62M | Investing Cash Flow |
| 83.74K | -190.38K | -468.73K | -310.09K | -7.86K | Financing Cash Flow |
| 3.61M | 4.29M | -962.06K | 5.15M | 14.52M |
Imagion Biosystems Ltd. Technical Analysis
Imagion Biosystems Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$17.01M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
52 Neutral | $5.15B | 3.02 | -44.64% | 2.83% | 16.44% | -0.47% | |
50 Neutral | AU$723.24M | ― | -112.97% | ― | ― | -84.82% | |
46 Neutral | $2.21B | ― | -21.31% | ― | ― | ― | |
38 Underperform | AU$2.62M | ― | ― | 55.07% | 88.20% | ||
36 Underperform | $3.98M | ― | -119.28% | ― | ― | 64.10% |
Imagion Biosystems Ltd. Corporate Events
Imagion Biosystems Limited has announced that its Annual General Meeting (AGM) will be held virtually on May 30, 2025. Shareholders are encouraged to access meeting materials online and submit their proxy votes ahead of the meeting. The virtual format allows shareholders to participate by asking questions and voting on resolutions, ensuring engagement despite the lack of a physical gathering.
Imagion Biosystems has released its quarterly activity report for Q1 FY2025, highlighting progress in its MagSense® HER2 breast cancer imaging agent program. The company is preparing to file an Investigational New Drug (IND) application with the U.S. FDA, which would enable the next phase of clinical studies. Manufacturing of the imaging agent is underway, and discussions with leading hospitals and cancer centers in the U.S. are ongoing. The company expects to file the IND in the third quarter and begin the Phase 2 study in the latter half of the year. Additionally, research and development for prostate and ovarian cancer programs are anticipated to commence later in the year, contingent on funding. The company reported a cash balance of AU$1.71 million at the end of March 2025, with increased operating cash outflows due to R&D expenditures.
Imagion Biosystems Ltd. has announced a new application for the quotation of securities on the ASX, following the exercise of options or conversion of other convertible securities. This move is part of the company’s ongoing efforts to enhance its financial flexibility and market presence, potentially impacting its operational capabilities and offering new opportunities for stakeholders.
Imagion Biosystems Ltd. has announced an analysis of its holdings, revealing a total of 97.5 million units with a significant concentration among a few major stakeholders. The release highlights the company’s strategic positioning in the market, with a focus on maintaining strong relationships with key investors, which could impact its financial stability and growth prospects.
Imagion Biosystems Ltd. announced the application for the quotation of 75,000,000 new securities on the ASX, with options expiring on December 13, 2027, at an exercise price of $0.04. This move is likely to impact the company’s financial structure and market presence, potentially offering new opportunities for investment and growth within the biotechnology sector.
Imagion Biosystems Ltd. has issued a cleansing prospectus for the offer of up to 1,000 new options at a nominal price, primarily to remove trading restrictions on these options. This move is part of the company’s compliance with regulatory obligations and is intended to facilitate the trading of its securities. The prospectus highlights the speculative nature of the investment and advises potential investors to seek professional advice. This announcement underscores the company’s commitment to maintaining transparency and regulatory compliance, which may enhance its credibility and attractiveness to investors.
Imagion Biosystems has announced that its 2025 Annual General Meeting (AGM) will be held on May 30, 2025, with the deadline for director nominations set for April 8, 2025. This announcement is a procedural update, ensuring stakeholders are informed about the upcoming AGM and the process for director nominations, reflecting the company’s commitment to transparency and governance.
Imagion Biosystems Limited has announced a breakthrough in molecular magnetic resonance imaging, which could significantly enhance cancer detection capabilities. This development is expected to impact the company’s operations positively, potentially strengthening its position in the medical imaging industry and offering new opportunities for stakeholders.
Imagion Biosystems Ltd. has released its corporate governance statement for the financial year ending December 31, 2024, which is now available on their website. This statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting its commitment to transparency and accountability in its operations. The disclosure is part of the company’s efforts to maintain high standards of corporate governance, which is crucial for building investor trust and ensuring regulatory compliance.
Imagion Biosystems Limited has released its annual report for the year ended 31 December 2024. The report includes comprehensive financial statements and disclosures, providing insights into the company’s financial health and operational performance over the past year. This release is crucial for stakeholders as it offers a detailed overview of the company’s financial position and strategic direction.